chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Lost my sense of taste and smell; Lost my sense of taste and smell; Body is achy; I felt pretty lousy; Very tired; This is a spontaneous report from a contactable consumer (Patient). A patient of unspecified age and gender received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Formulation: Solution for injection, Lot number: EW0181; Expiration Date was reported as 11Jun2021), via an unspecified route of administration on 11Jun2021 (reported as Friday evening) as single dose for COVID-19 immunization. Medical history included cough from unspecified date in Jun 2021 reported as about a week prior to getting the shot but get bronchitis a lot and gets sick at anything but had no other symptoms other than cough, bronchitis. The patient concomitant medications were not reported. It was reported that the patient took vaccine on Friday evening and felt pretty lousy all weekend and actually had almost every symptom of COVID right now, so she asked what happen if got the shot if you already had COVID. Patient stated that she lost sense of taste and smell, body is achy, very tired Patient stated that she get sick at anything but had no other symptoms other than cough and usually gets bronchitis. But then after the vaccine I started getting all the mentioned symptoms. The outcome of the events was unknown.  Consumer was unwilling to complete the report. Hence, limited information available.  No follow up attempts are possible. No further information is expected.
I started paxlovid the day I tested positive; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (I started paxlovid the day I tested positive) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Paroxysmal atrial fibrillation, Degenerative disc disease (degeneration of spinal discs), Latex allergy, Sulfonamide allergy (allergy to sulfa) and Silicone allergy. Concomitant products included GABAPENTIN from 15-Sep-2016 to an unknown date, MELOXICAM from 15-Sep-2016 to an unknown date, SOTALOL from 15-May-2018 to an unknown date, FAMOTIDINE from 01-Sep-2021 to an unknown date and ROSUVASTATIN from 10-Mar-2022 to an unknown date for an unknown indication.    On 13-May-2022, the patient received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 21-May-2022, the patient experienced COVID-19 (I started paxlovid the day I tested positive). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 21-May-2022 to 25-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (I started paxlovid the day I tested positive) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 21-May-2022, SARS-CoV-2 test: positive (Positive) Tested Positive on the day patient took paxlovid. On 03-Jun-2022, SARS-CoV-2 test: positive (Positive) Positive.         Patient tested positive on day 14 at the second time after taking Paxlovid, on 04-Jun 2022. Recurrence of Covid symptoms happened 14 days after first positive test on 04-Jun-2022 which was not recovered.  Patient previously received a COVID-19 Vaccine. Device date was reported as 05-Jun-2022  Company comment: This spontaneous case concerns a patient of unknown age and gender with no relevant medical history who experienced the unexpected non serious AESI of COVID 19 which occurred 8 days after the administration of fourth dose of mRNA-1273 vaccine in COVID 19 vaccination series. Patient received NIRMATRELVIR, RITONAVIR (Paxlovid) for the treatment of COVID-19 from 21-May to 25-May. Patient tested positive again for COVID 19 on day 14 of starting the treatment. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This spontaneous case concerns a patient of unknown age and gender with no relevant medical history who experienced the unexpected non serious AESI of COVID 19 which occurred 8 days after the administration of fourth dose of mRNA-1273 vaccine in COVID 19 vaccination series. Patient received NIRMATRELVIR, RITONAVIR (Paxlovid) for the treatment of COVID-19 from 21-May to 25-May. Patient tested positive again for COVID 19 on day 14 of starting the treatment. The benefit-risk relationship of mRNA-1273 is not affected by this report.
I had symptoms of a cold. Received a positive COVID-19 test. My symptoms were mild. I called my doctor and they advised me to get an antibody treatment. The next day, I went to a lab and got an antibody treatment. My symptoms lasted for approximately 10 days. I called the doctor due to nasal drainage and was put on Prednisone.
A large red welt appeared on my arm, over the injection site, one week after receiving the first done of the Moderna vaccine.  It has been an additional 7 days and the red mark has not faded
sore arm for a day after dose; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non-HCP).  A female patient (not pregnant) received BNT162b2 (BNT162B2), as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Dose: 1, UNKNOWN MANUFACTURER), for Covid-19 Immunization; Covid-19 vaccine (Dose: 2, UNKNOWN MANUFACTURER), for Covid-19 Immunization. The following information was reported: PAIN IN EXTREMITY (non-serious), outcome "unknown", described as "sore arm for a day after dose". It was unknown if therapeutic measures were taken as a result of pain in extremity.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Fever, shivering, stomach ache, tiredness (onset 27 hours post vaccine, symptoms ceased 37 hours post vaccine)
Information has been received from a health professional concerning a 12 month old male patient with no pertinent medical history and no known allergies who on 17-AUG-2009 was vaccinated SQ with a dose of VARIVAX (Merck) (lot number664721/0859Y). Concomitant vaccine therapy included a dose of MMR II (MSD), ACTHIB (unspecified), pneumococcal conj vaccine (unspecified) all given on 10-AUG-2009 and poliovirus vaccine and VAQTA (unspecified) given on 17-AUG-2009. It was reported that the patient possibly had an allergic reaction. The patient start to be fussy on the night of 18-AUG-2009 and then little spots were developing. It was reported that the patient looked like he had chickenpox from head to toe with papules all over. Medical attention has been sought by phone call and office visit. There were no lab studies performed. The patient was given an antihistamine (unspecified). At the time of the report, the patient had not recovered. Follow-up information has been received from the physician assistant concerning the patient with history of otitis media, bronchiolitis and pneumonia who on 17-AUG-2009 was vaccinated with a dose of VARIVAX (Merck). On 18-AUG-2009 the patient developed rash over entire body. There was no lab studies performed. The patient was ordered BENADRYL. On an unspecified date the patient's rash resolved. Additional information is not expected.
Provider placed the order for the patient to receive the following vaccines at the time of the office visit: MMR, Varicella, PCV13, Hep A . The medical assistant administered the following vaccines instead: MMRV, Varicella, PCV13, Hep A.  The provider was notified at the time of the event as well as the family.  The patient did not experience any adverse reaction to the additional dose of the varicella vaccine.  Nurse coordinator and Nurse supervisor were notified as well as coaching completed with the medical assistant and anyone that is authorized to administer vaccines in the clinic  in order to prevent any future mistakes.  Did also separate and label the vaccines larger and more clear so that there is no confusion in the future when administering  those particular vaccines.
diffuse body urticaria;generalized erythema;cardiac palpations, temp, hot flashes;
injection site area was red; injection site was swollen; injection site area was painful; injection site area was warm to touch; This is a spontaneous report from a contactable nurse and consumer. A 72-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) first dose, lot number: EL9265, intramuscular on 29Jan2021 11:30 at a single dose in the left arm for COVID-19 immunization.  Medical history included asthma from 2010, hypothyroidism diagnosed in 2000, obesity from 1995, hypertension from 2000. She has allergies to medications and environmental, allergic to Gadolinium dye. She had an anaphylactic reaction in a hospital, mostly due to food and environmental. No additional vaccines administered on the same date and no prior vaccinations within 4 weeks. Concomitant medication included benralizumab (FASENRA PEN) for asthma (taking for a couple of years).  The patient previously took hydrochlorothiazide and experienced allergy. The patient received the first covid vaccine dose on 29Jan2021 and was fine until this morning (11Feb2021 at 9:00) when she woke up and the left arm injection site area was red, swollen, painful and warm to touch. Her height was under 5 feet. The outcome of the events was not recovered. The events Left arm injection site area is red, swollen, painful and warm to touch were assessed as serious-medically significant. Causality of the events to the suspect drug was related.; Sender's Comments: The Company cannot completely exclude the possible causality between the reported "the left arm injection site area was red, swollen, painful and warm to touch" and the administration of the COVID-19vaccine, BNT162B2, based on the reasonable temporal association.   The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to RA, IEC, as appropriate.
no side effects; Improperly stored vaccine was administered; This spontaneous report was received from a nurse referring to a patient of unknown age and gender.  The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported.  On 12-JUL-2023, the patient was vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live recombinant human albumin (rHA) (PROQUAD) injection, administered for prophylaxis (lot# W012730, expiration date: 16-OCT-2023; strength and route of administration were not provided). The vaccine was improperly stored at 6 degrees Celsius for 7 hours. There was no previous temperature excursion (Product storage error). No side effects were reported.  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-2309USA008482: US-009507513-2309USA008465: US-009507513-2309USA008212: US-009507513-2309USA008121:
Arrhythmia; Tachycardia, BP 103/min; This is a spontaneous report from a contactable other HCP.   A 25-year-old female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot number: EL9264) on 05Feb2021 at single dose via an unspecified route of administration on left arm for COVID-19 immunization. The patient received first dose of BNT162B2 on 14Jan2021 at 03:45 pm on left arm. Concomitant medications were not reported. On 05Feb2021 at 15:00 the patient experienced Tachycardia with BP 103/min and Arrhythmia. No treatment was given for reported events. At the time of the reporting the patient had not yet recovered from the events.   The information on the lot/batch number has been requested.; Sender's Comments: Based on the temporal relationship, the association between the event arrhythmia with BNT162b2 can not be completely excluded.  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.
my last flu shot made me very ill; Initial information received on 29-Nov-2020 regarding an unsolicited valid non-serious social media case from a consumer (patient) via social media.  This case involves a patient of unknown demographics, who reported my last flu shot made me very ill (illness), when received Influenza vaccine.  The patient's medical history, medical treatments, vaccinations, condition medications and family history were not provided.  On an unknown date, the patient received influenza vaccine (batch number and expiry date unknown) via an unknown dose via unknown route at unknown administration site for prophylactic vaccination.  On an unknown date, (latency: unknown) after starting the suspect vaccine therapy, the patient stated my last flu shot made me very ill (illness) patient would never get it.  No lab data was reported.  It was not reported if the patient received any corrective treatment.  At the time of report, the event outcome was unknown for illness.  There will be no information available on the batch number for this case.
This spontaneous report as received from a nurse refers to unspecified number of patients of unknown age and gender. The patient's medical history, concurrent conditions and concomitant medications were not reported. The nurse provided that in May 2016, she had a temperature excursion (to 34.4F for 8 hours and 24 minutes), with RECOMBIVAX HB (lot# L038499 with expiration date 26-JUN-2017). On unknown dates in 2016, the patients were administered the improperly stored doses of RECOMBIVAX HB (dose and route were not reported). On an unknown date in 2016, the vaccines has a second excursion to 28.9F for 8 hours cycling every 20 minutes. No vaccines were administered since the second excursion. This is on of several reports received from the same reporter. Additional information has been requested.
If you draw a midline from top of my head down through abdomen - anything on my right side of my body is where I had reduced skin sensation. When my right side feels cold the left side feels hot. That nerve sensation today a little better but not too much - it has gone from a 1 to a 1 1/2 so it definitely hasn't gotten better.  I have weakness in my right hip and leg. I am having some right leg pain that starts at the top and goes to the bottom of foot. My mobility is suffering.  I have an MRI coming up on my head on the 26th.  No treatment at all so far. I have a neurologist appt coming up next Wednesday.
COVID-19; COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 37-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 12Feb2021 as dose 1, single (Lot number: El9264), in left arm and on 05Mar2021 as dose 2, single (Lot number: Eng6206) at the age of 36 years, in left arm for covid-19 immunisation; coviD-19 vaccine mrna (mrna 1273) (MODERNA COVID-19 VACCINE), on 10Nov2021 as dose 3 (booster), single (Batch/Lot number: unknown), in left arm for covid-19 immunisation. The patient had no relevant medical history. The patient's concomitant medications were not reported. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 16Apr2022, outcome "unknown" and all described as "COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (16Apr2022) Positive, notes: positive PCR 16Apr; (17Apr2022) Positive, notes: Positive rapid antigen tests 17Apr and 19Apr; (19Apr2022) Positive, notes: Positive rapid antigen tests 17Apr and 19Apr; (22Apr2022) Positive, notes: Negative rapid antigen test 22Apr; (04May2022) Positive, notes: Positive rapid antigen tests 4May and 5May; (05May2022) Positive, notes: Positive rapid antigen tests 4May and 5May. Therapeutic measures were taken as a result of vaccination failure, covid-19.  Follow-up attempts are completed. No further information is expected.
Pt felt short of breath starting around midnight about 8 hrs after first dose of COVID vaccine.  Discomfort in middle and upper part of chest
Patient received her PREVNAR 13 on 5-1-2015. Two days later she noted redness and soreness at the injection site. Two days later symptoms reduced significantly. 1-2 days later symptoms became worse. Patient went to her local urgent care where she received a steroid injection, BENADRYL injection and prescribed sulfamethoxazole/trimethoprim 800/600 mg 1 tablet twice daily for 12 days and mupirocin 2% ointment.
after the vaccination same day i had tingling in my arms and legs and sharp pain in my chest and contacting my doctor the next day and they told me to go to there and they did the ekg and then i went to the doctor and they did the blood work. i still have the tingling in my legs and my blood pressure is really high
Pt Noticed a rash on R arm near the site and then the rash spread down both arms and to trunk and legs. Rash was itch and then produced scabbing.
Information has been received for a case in litigation from information obtained from a published article concerning a female patient with autosomal recessive nonsyndromic deafness who was vaccinated with PEDVAX HIB. Concomitant vaccination included diphtheria toxoid (+) pertussis vaccine (unspecified) (+) tetanus toxoid. Subsequently the patient experienced bilateral sensorineural hearing loss. At the time of the report, the patient was 12 years old and her outcome was unknown. Upon internal review bilateral sensorineural hearing loss was considered an other important medical event. No further information is available. A copy of the published literature article is attached as further documentation of the patient's experience.
Exactly the 8th day after vaccine my injection site got about a  3? red spot on my skin with some slight morning and evening itching. Was not hot to touch. Symptoms lasted about 2 1/2 days. Just put Cetaphil on it.
A couple days after my vaccine, I began to get itching and pain on my chin. I could feel burning and pain. I also started to form a scab on my bottom lip. I could feel a welt come up and I felt shooting pain from my ear down to my jawline. I went over to the clinic and the PA there thought it was shingles. I was tested for shingles and it did come back positive. After taking the VALTREX, my symptoms began to slowly go away however the headaches continued. Now I get random nerve tingling down my right side around my neck and shoulder area.
10.1.22: vax received 12pm; reactions started ~8pm: 101 F fever, shuddering, chills, sweating, full body aches, headache, fatigue, very sore arm, warm at injection site. Today is 10.3.22, same reactions, no improvement yet.
The pt experienced localized erythema to the left arm within 24 hours. Treated with Benadryl changed by the ER to Zyrtec.
This is a spontaneous report received from a contactable consumer or other non-HCP. A male patient received unknown dose number of BNT162B2 (Pfizer-BioNTech COVID-19 vaccine, batch/lot# unknown), on Sep 10, 2021, at 11:45, single dose, for COVID-19 immunisation. Medical history and concomitant medications not reported. The patient experienced dysgeusia (husband received the same vaccine at the same time and also developed metallic taste in his mouth), onset Sep 10, 2021, with outcome of unknown. No follow-up attempts possible. Information about batch/lot number cannot be obtained. No further information expected. Follow-up (Oct 14, 2021): This follow-up submitted to notify the batch/lot number is not available despite the follow-up attempts made. Follow-up attempts completed. No further information expected.
ADULT OBSTRUCTIVE SLEEP APNEA, SEVERE 1/29/2023 HX OF ACUTE KIDNEY INJURY ACUTE HYPOXEMIC RESPIRATORY FAILURE 8/11/2022 HX OF ACUTE KIDNEY INJURY HYPOXIA 8/10/2022 HX OF ACUTE KIDNEY INJURY ADULT OBSTRUCTIVE SLEEP APNEA, SEVERE 1/29/2023 ABDOMINAL AORTIC ANEURYSM, UNSPECIFIED PART ACUTE HYPOXEMIC RESPIRATORY FAILURE 8/11/2022 ABDOMINAL AORTIC ANEURYSM, UNSPECIFIED PART HYPOXIA 8/10/2022 ABDOMINAL AORTIC ANEURYSM, UNSPECIFIED PART ADULT OBSTRUCTIVE SLEEP APNEA, SEVERE 1/29/2023 PATIENT NONCOMPLIANCE W DIETARY REGIMEN DUE TO UNSPECIFIED REASON ACUTE HYPOXEMIC RESPIRATORY FAILURE 8/11/2022 PATIENT NONCOMPLIANCE W DIETARY REGIMEN DUE TO UNSPECIFIED REASON HYPOXIA 8/10/2022 PATIENT NONCOMPLIANCE W DIETARY REGIMEN DUE TO UNSPECIFIED REASON ADULT OBSTRUCTIVE SLEEP APNEA, SEVERE 1/29/2023 DIASTOLIC HEART FAILURE, ACUTE ON CHRONIC ACUTE HYPOXEMIC RESPIRATORY FAILURE 8/11/2022 DIASTOLIC HEART FAILURE, ACUTE ON CHRONIC HYPOXIA 8/10/2022 DIASTOLIC HEART FAILURE, ACUTE ON CHRONIC ADULT OBSTRUCTIVE SLEEP APNEA, SEVERE 1/29/2023 ADULT OBSTRUCTIVE SLEEP APNEA, SEVERE ACUTE HYPOXEMIC RESPIRATORY FAILURE 8/11/2022 ADULT OBSTRUCTIVE SLEEP APNEA, SEVERE HYPOXIA 8/10/2022 ADULT OBSTRUCTIVE SLEEP APNEA, SEVERE
he had a little bit of a funny taste which tasted like metal; This is a spontaneous report from a contactable consumer (patient) via Pfizer-sponsored program COVAX US Support. A male patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection), dose 1 via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as 1st dose, single dose for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. Patient was concerned about the minor reaction that he experienced with the first dose of the Pfizer COVID-19 vaccine. After 20 minutes or so while patient was walking back to his car, he had a little bit of a funny taste which tasted like metal. It was funky. It lasted 30 seconds and went away. Outcome of event was recovered on an unspecified date.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Feeling rough and not fine; Low grade temperature; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (Feeling rough and not fine) and PYREXIA (Low grade temperature) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 06-Dec-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-Dec-2021, the patient experienced VACCINATION COMPLICATION (Feeling rough and not fine) and PYREXIA (Low grade temperature). At the time of the report, VACCINATION COMPLICATION (Feeling rough and not fine) and PYREXIA (Low grade temperature) had not resolved.            Concomitant information was not provided.   Treatment information was not provided.
On the first day, I felt exhausted, then a little woozy with a sore arm, but nothing else. Then a couple days later my armpit lymphs started to grow and get sore and continued to grow until 9 days out. At 6 days in the evening, I started to feel tired and that night I had a runny nose and soreness where my nasal passage hits the back of my throat. This continued for a day with exhaustion, and I felt sick with the flu. There was no cough. The peak flu feeling lasted for 3 days and corresponded with the swelling of my lymphs, then symptoms subsided along with the lymph swelling. Now at 2 weeks out, I feel back to normal.
This was my first booster. I had gotten Moderna for my vaccine. I got Costochondritis. I went to the ER and was given a dose of anti inflammatory meds. It went away after that.
11/19/09 9:30 PM-12:30 AM Diarrhea, nausea and scratchy throat. Since then I have come down with sinus congestion symptoms-tickling in throat, cough and sinus drainage.
Experiencing sore in arm, headache, chills, and an enlarged gland under the left arm. These symptoms are still ongoing despite taking Tylenol for 3 days